Inhibitors of fibrinolysis are elevated in atherosclerotic plaque

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 4, 1996, Pages 539-545

  Robbie, Linda A ^a   Booth, Nuala A ^a   Brown, Paul A J ^a   Bennett, Bruce ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

atherosclerosis; fibrinolysis; PAI 1; 2 AP

Indexed keywords

ANTIPLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; ENZYME ACTIVITY; ENZYME REGULATION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; TISSUE REPAIR;

EID: 0029871475     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.4.539     Document Type: Article

References (39)

1. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985;44:139-266.
2. Booth NA. The natural inhibitors of fibrinolysis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Haemostasis and Thrombosis, Vol 3. 3rd ed. Edinburgh, Scotland: Churchill Livingstone; 1994:699-717.
3. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-333.
4. Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res. 1984;33:523-530.
5. Kruithof EKO, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost. 1988;59:7-12.
6. Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Semin Thromb Hemost. 1988;14:180-183.
7. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost. 1995;74:71-76.
8. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis. 1990;10:263-275.
9. Kadish JL, Butterfield CE, Folkman J. The effects of fibrin on cultured vascular endothelial cells. Tissue Cell. 1979;11:99-108.
10. Smith EB, Staples EM, Dietz HS, Smith RH. Role of endothelium in segmentation of lipoprotein and fibrinogen in aortic lesions, thrombi and graft pseudointima. Lancet. 1979;2:812-816.
11. Smith EB, Staples EM. Haemostatic factors in human aortic intima. Lancet. 1981;1:1171-1179.
12. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis. 1991;5:197-206.
13. Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors: implications for the pathogenesis of atherosclerosis. Arteriosclerosis. 1989;9:269-278.
14. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 1990;82:1485-1493.
15. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266:9419-9427.
16. Robbie LA, Bennett B, Brown PAJ, Croll AM, Booth NA. Activators and inhibitors of the fibrinolytic system in human thrombi. Thromb Haemost. In press.
17. MacGregor IR, Booth NA. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI). Thromb Haemost. 1988;59:68-72.
18. MacGregor IR, MacDonald S, Dawes J, Mickelm LR, James K. A monoclonal antibody enzyme-linked immunosorbent assay (ELISA) directed towards a fibrin binding region of tissue-type plasminogen activator. Fibrinolysis. 1987;1:247-253.
19. Booth NA, Groll AM, Bennett B. The activity of plasminogen activator inhibitor-1 (PAI-1) of human platelet. Fibrinolysis. 1990;4(suppl 2):138-140.
20. Nakane PK, Kawaoi A. Peroxidase-labeled antibody: a new method of conjugation. J Histochem Cytochem. 1974;22:1084-1091.
21. Deutsch DG, Mertz ET. Plasminogen purification from human plasma by affinity chromatography. Science. 1970;170:1095-1096.
22. MacGregor IR, Tonner AM, Mickelm LR, James K, Booth NA. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (PAI-1). Fibrinolysis. 1990;4:27-34.
23. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Mac-Donald S, Pulford A, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32:219-229.
24. Booth NA, MacGregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from human endothelial cells: purification and partial characterization. Eur J Biochem. 1987;165:595-600.
25. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator (PAI-1) in tissues. J Clin Pathol. 1991;44:139-143.
26. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
27. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
28. Laiho M, Keski Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989;49:2533-2553.
29. Declerck PJ. De Mol M, Alessi M-C. Baudner S, Pâques E-P, Preissner KT, Müller-Berghaus G, Collen D. Purification and char- acterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem. 1988;263:15454-15461.
30. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: evidence that the protein is vitronectin. J Biol Chem. 1989;264:936-939.
31. Seiffert D, Wagner NN, Loskutoff DJ. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol. 1990;266:2824-2830.
32. Hetland G, Pettersen HB, Mollnes TE, Johnson E. S-protein is synthesized by human monocytes and macrophages in vitro. Scand J Immunol. 1989;29:15-21.
33. Roger M, Halstensen TS, Hogasen K, Mollnes TE, Solum NO, Hovig T. Platelets and vitronectin: immunocytochemical localization and platelet interaction with exogenously added vitronectin. Nouv Rev Fr Hematol. 1992;34:47-54.
34. Underwood MJ, de Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res. 1993;27:882-885.
35. Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood. 1987;69:1600-1604.
36. 2-macroglobulin and Cl-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor. Blood. 1990;75:671-676.
37. Pinches SA, Moore NR, Booth NA. Cl-inhibitor as an inhibitor of tissue plasminogen activator (t-PA). Br J Haematol. 1994;86(suppl 1):46. Abstract.
38. Kruithof EKO. Biological evaluation of the fibrinolytic system. Fibrinolysis. 1993;7:7-9.
39. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor β is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.